Please check your internet connection and try again.
# Tagenixim (Cefixime)
## Overview
Tagenixim is a brand name for **Cefixime**, a third-generation cephalosporin antibiotic. It acts by inhibiting bacterial cell wall synthesis. It is stable against many beta-lactamases and is administered orally.
## Primary Indications
* Uncomplicated urinary tract infections (UTIs)
* Otitis media
* Pharyngitis and tonsillitis
* Acute bronchitis and acute exacerbations of chronic bronchitis
* Uncomplicated gonorrhea (cervical/urethral/rectal)
## Adult Dosing
* **Standard infections:** 400 mg daily, administered as a single dose or in two divided doses (200 mg every 12 hours).
* **Uncomplicated gonorrhea:** 400 mg as a single oral dose.
## Pediatric Dosing
* **Children ≥ 6 months:** 8 mg/kg/day, administered as a single daily dose or in two divided doses (4 mg/kg every 12 hours).
* **Maximum:** 400 mg daily.
* *Note: Safety and efficacy in infants < 6 months have not been established.*
## Dose Adjustments
* **Renal Impairment:**
* Creatinine Clearance (CrCl) 21–60 mL/min: Reduce dose by 25% (e.g., 300 mg daily).
* CrCl < 20 mL/min: Reduce dose by 50% (e.g., 200 mg daily).
* **Hepatic Impairment:** No standard dosage adjustment required; cautious use is advised.
## Contraindications
* Known hypersensitivity to cefixime or other cephalosporins.
* History of severe allergic reactions (e.g., anaphylaxis, Stevens-Johnson syndrome) to penicillins or other beta-lactams.
## Adverse Effects
* **Common:** Diarrhea (often dose-related), abdominal pain, nausea, dyspepsia, flatulence.
* **Serious:** *Clostridioides difficile*-associated diarrhea (CDAD), severe hypersensitivity reactions (anaphylaxis), seizures (rare, primarily in renal impairment), and hematologic abnormalities (leukopenia, thrombocytopenia).
## Key Drug Interactions
* **Anticoagulants:** May enhance the effects of warfarin (monitor INR).
* **Probenecid:** Increases serum concentrations of cefixime by inhibiting renal tubular secretion.
* **Nifedipine:** May increase the bioavailability of cefixime.
## Monitoring
* Monitor for signs of hypersensitivity.
* In prolonged therapy, assess renal, hepatic, and hematopoietic functions periodically.
* Monitor for persistent diarrhea or signs of *C. difficile* infection.
## Clinical Pearls
* Cefixime does **not** provide adequate coverage for *Staphylococcus aureus* or *Enterococcus* species.
* Bioavailability is not significantly affected by food intake; however, oral suspensions may be better tolerated if taken with food.
* Patients with a history of penicillin allergy should be monitored closely if prescribed a cephalosporin due to potential cross-reactivity (usually estimated at <5-10%).
* Consult institutional antimicrobial stewardship guidelines, as local resistance patterns for gram-negative organisms vary.
***
**Educational Disclaimer:** This information is for educational purposes only and does not constitute medical advice. Prescribing information must be verified against the official product labeling, institutional protocols, and current clinical guidelines before administration. Consult a qualified healthcare professional for medical decision-making.
